Houston, TX, Sept. 14, 2017 -- Heart patients, family members, caregivers and medical professionals from across the country are expected to participate in the Mended Little Hearts CHD Symposium September 22-23, 2017 in Houston, Texas. The two-day event will be held at Texas Children’s Hospital and includes an ‘Out of this World’ reception, a tour of Texas Children’s Hospital Heart Center and entrance to the Houston Astros game Saturday evening.
|
||||||
The conference is open to anyone affected by congenital heart disease and will feature multiple speakers, including panels on supporting teens and families during their transition to adult CHD care, innovations in CHD treatment, collaborative innovations that improve lives, caring for the needs of the child and family, and more.
"I am truly excited that we are bringing our CHD Symposium to Houston,” said Donnette Smith, President of Mended Hearts and Mended Little Hearts. “Not only will participants hear about the latest innovations in CHD research and treatment, but they’ll learn how collaboration between medical staff, patients and caregivers can help improve the lives of those affected by CHD. They’ll also have the unique opportunity to network with other patients and families who have gone through what they’ve experienced.”
To register for the MLH CHD Symposium, please go to:
https://events.r20.constantcontact.com/register/eventReg?oeidk=a07eee1g3j58e69d9a0&oseq=&c=&ch=
Mended Little Hearts gratefully acknowledges the support of our Symposium sponsors: Edwards Lifesciences, Abbott, Prolacta, Syncardia, and Medtronic.
About Mended Little Hearts
Mended Little Hearts plays a significant role in the lives of families with children diagnosed with congenital heart defects. Through its local support group meetings, health education to communities, hospital support programs, disease awareness activities, and advocacy on issues that affect our families, Mended Little Hearts provides hope, help and healing so families can be families and kids can be kids. Mended Little Hearts is a program of The Mended Hearts Inc., a non-profit, volunteer-based organization providing hope, help and healing to heart patients and their families since 1951.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/67752cc8-cf16-42d3-b3cc-f4d6ec61163a
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/edf18634-9cba-4314-903b-5c85472e03a7
Mandy Sandkuhler Mended Little Hearts 4698883400 [email protected]


ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Italy Fines Apple €98.6 Million Over App Store Dominance
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



